News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 European Hematology Association Congress


5/29/2013 10:04:49 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NATICK, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announced that data for its lead compound KPT-330 against advanced chronic myeloid leukemia (CML) will be presented in the CML Biology oral abstract session at the 18th Congress of the European Hematology Association (EHA) to be held June 13th – 15th, 2013 in Stockholm, Sweden.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES